John Jacob Marchalonis from 5661 Camino Arturo, Tucson, AZ 85718, Phone: 5207421048

Isbn (Books And Publications)

Self/Non-Self Discrimination
view source
Author:

John J. Marchalonis
ISBN #:

0306402637

Comparative Immunology
view source
Author:

John J. Marchalonis
ISBN #:

0632002182

Comparative Immunology
view source
Author:

John J. Marchalonis
ISBN #:

0470151609

Antibody As A Tool: The Applications Of Immunochemistry
view source
Author:

John J. Marchalonis
ISBN #:

0471100846

Defense Molecules: Proceedings Of A Ucla Colloquium Held At Lake Tahoe, California, February 20-27, 1989
view source
Author:

John J. Marchalonis
ISBN #:

0471567388

Immunity In Evolution
view source
Author:

John J. Marchalonis
ISBN #:

0674444450

The Lymphocyte: Structure And Function
view source
Author:

John J. Marchalonis
ISBN #:

0824764188

The Lymphocyte: Structure And Function
view source
Author:

John J. Marchalonis
ISBN #:

0824777972

Us Patents

Modulation Of Immune Response And Methods Based Thereon
view source
US Patent:

7323174, Jan 29, 2008
Filed:

Jun 12, 2000
Appl. No.:

09/591789
Inventors:

John J. Marchalonis - Tucson AZ, US
Ronald R. Watson - Tucson AZ, US
Samuel F. Schluter - Tucson AZ, US
Assignee:

Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
International Classification:

A61K 39/21
US Classification:

4241851, 4242081
Abstract:

The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof. The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods.

Dimerized T-Cell Receptor Fragment, Its Compositions And Use
view source
US Patent:

7998926, Aug 16, 2011
Filed:

May 17, 2002
Appl. No.:

10/478194
Inventors:

John Jacob Marchalonis - Tucson AZ, US
Ronald Ross Watson - Tucson AZ, US
Assignee:

The Arizona Boad of Regents on Behfl of the University of Arizona - Tucson AZ
International Classification:

A61K 38/10
US Classification:

514 38, 530327
Abstract:

Dimers of a peptide from the T-cell receptor (Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr) (SEQ ID NO:1) are disclosed for preventing the progression to AIDS in an animal model. Methods for delaying the progression to AIDS and restoring normal immunological responses in an animal model following infection are shown and comprise administering through various systemic routes dimeric T-cell receptor peptide Vβ CDR1 to restore normal levels of Th1 cytokines interleukin 2 and interferon-γ, which are suppressed following infection, and those of Th2 derived cytokines interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G, which are stimulated following infection.

Modulation Of Immune Response And Methods Based Thereon
view source
US Patent:

20070172450, Jul 26, 2007
Filed:

Mar 19, 2007
Appl. No.:

11/687952
Inventors:

John MARCHALONIS - Tucson AZ, US
Ronald Watson - Tucson AZ, US
Samuel Schluter - Tucson AZ, US
Assignee:

University of Arizona - Tucson AZ
International Classification:

A61K 48/00
A61K 38/20
A61K 38/19
A61K 38/21
A61K 38/16
C07K 14/47
US Classification:

424085100, 514014000, 530326000, 424093200, 435456000, 424085200, 424085600
Abstract:

The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods. The peptides are selected from the group consisting of Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO: 11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO: 12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof.

Modulation Of Immune Response And Methods Based Thereon
view source
US Patent:

20080171060, Jul 17, 2008
Filed:

Jan 28, 2008
Appl. No.:

12/011581
Inventors:

John J. Marchalonis - Tucson AZ, US
Ronald R. Watson - Tucson AZ, US
Samuel F. Schluter - Tucson AZ, US
International Classification:

A61K 39/00
C07K 7/08
C07K 7/06
A61P 37/06
A61P 37/04
A61P 37/02
A61P 37/08
A61K 38/08
A61K 38/10
US Classification:

4241851, 530326, 530329, 514 13, 514 16
Abstract:

The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof. The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods. The peptides are selected from the group consisting of Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val (SEQ ID NO:2), Leu Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:3), Leu Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala (SEQ ID NO:4), Leu Ile Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala (SEQ ID NO:5), Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser (SEQ ID NO:6), Leu Ala Ile Ser Gly Leu Glu Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala (SEQ ID NO:7), Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:8), Leu Thr Ile Ser Gly Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln (SEQ ID NO:9), Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser (SEQ ID NO:10) and Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln (SEQ ID NO:11), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Lys Leu Thr Val Val (SEQ ID NO:12), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Glu Leu Thr Val Val (SEQ ID NO:13), Ala Asn Tyr Gly Tyr Thr Phe Gly Ser Gly Thr Asp Leu Thr Val Val (SEQ ID NO:14), Thr Phe Gly Xaa Gly Thr Yaa, wherein Xaa is any amino acid and Yaa is Arg, Lys, Asp, Glu, His or other charged amino acid molecule (SEQ ID NO:15), or a derivative thereof.

Synthetic Senescent Cell Antigen
view source
US Patent:

51570203, Oct 20, 1992
Filed:

May 24, 1990
Appl. No.:

7/528210
Inventors:

Marguerite M. B. Kay - Temple TX
John J. Marchalonis - Tucson AZ
Assignee:

Research Corporation Tech., Inc. - Tucson AZ
International Classification:

C07K 708
A61K 3702
US Classification:

514 13
Abstract:

Disclosed herein is a synthetic senescent cell antigen comprised of purified peptides immunoreactive with antibodies to the naturally occurring antigen. Preferably, the synthetic senescent cell antigen comprises two peptides with the amino acid sequences SKLIKIFQDHPLQKTYN and LFKPPKYHPDVPYVKR, respectively. The antigen and peptides may be used in compositions, diagnostic kits, and methods for detecting or measuring antibodies to senescent cell antigen, studying cellular aging and autoimmune mechanisms, separating anions from a gas or liquid, or treating certain diseases.

T-Cell Receptor Peptides And Methods For Preventing The Progression To Aids In An Animal Model
view source
US Patent:

59119900, Jun 15, 1999
Filed:

Aug 13, 1996
Appl. No.:

8/696049
Inventors:

John J. Marchalonis - Tucson AZ
Ronald R. Watson - Tucson AZ
Keivan Dehghanpisheh - Portland OR
Yuejian Wang - St. Paul MN
Dennis S. Huang - Shaker Heights OH
Assignee:

Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
International Classification:

A61K 3900
A61K 4505
C07K 14725
US Classification:

4241851
Abstract:

A novel peptide from the T-cell receptor is shown to be effective in preventing the progression to AIDS in an animal model. Methods for delaying the progression to AIDS and restoring normal immunological responses in an animal model following infection are shown and comprise administering through various systemic routes T-cell receptor peptide V. beta. CDR1 to restore normal levels of Th1 cytokines interleukin 2 and interferon-. gamma. , which are suppressed following infection, and those of Th2 derived cytokines interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G, which are stimulated following infection.